Capstone Investment Advisors LLC Buys 47,536 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Capstone Investment Advisors LLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 108,665 shares of the company's stock after buying an additional 47,536 shares during the period. Capstone Investment Advisors LLC owned approximately 0.11% of Intellia Therapeutics worth $1,267,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Baker BROS. Advisors LP bought a new position in Intellia Therapeutics during the fourth quarter valued at about $7,510,000. Benjamin Edwards Inc. raised its stake in shares of Intellia Therapeutics by 11.1% in the fourth quarter. Benjamin Edwards Inc. now owns 64,065 shares of the company's stock valued at $747,000 after purchasing an additional 6,396 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Intellia Therapeutics by 78.0% in the fourth quarter. BNP Paribas Financial Markets now owns 438,458 shares of the company's stock worth $5,112,000 after purchasing an additional 192,096 shares during the period. Algert Global LLC boosted its stake in Intellia Therapeutics by 13.6% during the fourth quarter. Algert Global LLC now owns 69,354 shares of the company's stock worth $809,000 after buying an additional 8,312 shares in the last quarter. Finally, Aptus Capital Advisors LLC acquired a new position in shares of Intellia Therapeutics in the 4th quarter valued at $1,624,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. HC Wainwright started coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They set a "buy" rating and a $30.00 price objective for the company. Wolfe Research upgraded shares of Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 target price on the stock in a research note on Monday, April 21st. Finally, StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $36.47.

Intellia Therapeutics Stock Down 1.9 %

Intellia Therapeutics stock traded down $0.16 during midday trading on Friday, hitting $8.12. 5,135,177 shares of the stock were exchanged, compared to its average volume of 2,476,091. The company has a fifty day simple moving average of $8.13 and a two-hundred day simple moving average of $11.00. The stock has a market capitalization of $841.09 million, a PE ratio of -1.49 and a beta of 2.33. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. During the same quarter in the prior year, the firm posted ($1.12) earnings per share. Intellia Therapeutics's revenue for the quarter was down 42.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.